Shire Pharmaceuticals
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
-
Shire plc Release: BRAVE Awards 2012 to Recognize Caregivers Now Accepting Nominations
4/2/2012
-
Shire plc Hit by Bowel Drug Study Failure
4/2/2012
-
Shire plc Release: One Year Data Provide Evidence of Effectiveness and Tolerability of REPLAGAL(R) (agalsidase alfa) in Fabry Patients
3/30/2012
-
Shire plc Reaffirms Support of Patients Requiring Midodrine HCl; Advances FDA Agreed Upon Clinical Trials
3/30/2012
-
Heptares Grants Shire plc an Exclusive Worldwide $190 Million License to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3/20/2012
-
Shire plc Drops After Pulling US Application for Replagal, Move Gives Sanofi (France) a Boost
3/16/2012
-
Shire plc to Initiate Two Phase 4 Clinical Trials to Compare Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta® (methylphenidate HCl) Extended-Release Tablets, (CII)
3/6/2012
-
Shire plc Supports Rare Disease Day 2012
2/29/2012
-
arGEN-X Enters Into a Therapeutic Antibody Alliance With Shire plc
2/29/2012
-
Shire Pharmaceuticals Announces Judges Panel for Scholarship Program for Individuals with ADHD
2/14/2012
-
Another Strong Year for Shire plc With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34
2/10/2012
-
Shire plc Acquires US Rights to Resolor® (prucalopride)
1/10/2012
-
ICON Selected by Shire plc’s Specialty Pharmaceuticals Division as Global Strategic Partner for Clinical Research and Central Laboratory Services
1/9/2012
-
ICON Selected by Shire plc's Specialty Pharmaceuticals Division as Global Strategic Partner for Clinical Research and Central Laboratory Services
1/9/2012
-
Shire plc Reports Positive Phase II Results for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII)
12/8/2011
-
Shire Pharmaceuticals Announces Regulatory Filings in US and EU for New Manufacturing Facility
11/23/2011
-
Shire plc Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
11/18/2011
-
Shire plc Seeks Fast-Track Approval for Fabry Disease Drug
10/31/2011
-
Shire plc Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
10/28/2011
-
Shire plc Release: EU Study Shows Once-Daily Lisdexamfetamine Dimesylate (LDX) Effective for Symptom Control in Children and Adolescents with ADHD
10/21/2011